Consumption of Anti-Epileptic Drugs in Primary Health Care in Albania, 2004-2016
DOI:
https://doi.org/10.3889/oamjms.2019.719Keywords:
Drug utilisation, DDD, Anti-Epileptic drugs (AEDs), Morbidity, EpilepsyAbstract
BACKGROUND: Epilepsy is a serious neurological condition requiring sometimes lifelong pharmacological treatment, and continuous specialist monitoring.
AIM: To investigate the use of Anti-Epileptic Drugs (AEDs) in epilepsy, with focus on the exposure of AEDs, differences and changes in prescription patterns over time; to evaluate the relation between the consumption data of AED and the level of epileptic morbidity for the period 2004-2016.
STUDY DESIGN: Official data regarding the consumption of AEDs within Albania were collected retrospectively. Every year of the period, 2004-2016 has been considered separately.
METHODS: The data were assembled from Health Insurance Institute (HII) in Tirana, Albania and analysed for the period 2004-2016. The consumption of drugs was expressed as several Defined Daily Dose (DDDs)/1000 inhabitants/day. Also, for all the period under study 2004-2016, we analysed the data of import and domestic production of drugs, which represent the real consumption of drugs in the country. These data were subsequently involved in a comparative analysis with the utilisation data according to the HII, as well as through performing international comparisons of the consumption of AEDs drugs.
RESULTS: Epilepsy morbidity data indicate that there exists a correlation statistically significant between this disease and the trend of consumption of AEDs.
CONCLUSION: The present study suggests that the level of consumption for AEDs in Albania is very low when compared globally; with a decrease in the consumption of classic antiepileptic drugs and a parallel increase in the consumption of new generation drugs.
Downloads
Metrics
Plum Analytics Artifact Widget Block
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Laerta Kakariqi, Gentian Vyshka (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0